Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2017 | Drug resistance in multiple myeloma: addressing the issue

Drug resistance is a common problem in the treatment of multiple myeloma (MM), either through initial resistance to a drug, or a developed resistance associated with relapse. Speaking from the Myeloma 2017 meeting held in Edinburgh, UK, Brian Van Ness, PhD, of the University of Minnesota, Minneapolis, MN, outlines the talks given at the meeting regarding the problem of resistance, and the ways in which the MM community can address this issue.